Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy

  title={Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy},
  author={Nigishi Hotta and Yasuo Akanuma and Ryuzo Kawamori and Kempei Matsuoka and Yoshitomo Oka and Motoaki Shichiri and Takayoshi Toyota and Mitsuyoshi Nakashima and Isao Yoshimura and Nobuo Sakamoto and Yukio Shigeta},
  journal={Diabetes Care},
  pages={1538 - 1544}
OBJECTIVE—We sought to evaluate the long-term efficacy and safety of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor nerve conduction velocity (MNCV) ≥40 m/s, and HbA1c ≤9% were enrolled in this open-label, multicenter study and randomized to 150 mg/day epalrestat or a control group. After excluding the withdrawals, 289 (epalrestat group) and 305 (control group) patients were included in… 

Figures and Tables from this paper

Is epalrestat an effective treatment for diabetic peripheral neuropathy?
  • S. Tesfaye
  • Medicine
    Nature Clinical Practice Endocrinology &Metabolism
  • 2007
The Aldose Reductase Inhibitor–Diabetes Complications Trial was a 3-year, multicenter, open-label, randomized, controlled trial that concluded that epalrestat was an effective treatment for diabetic peripheral neuropathy.
Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy
It was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo, and may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy.
Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study
Teneligliptin not only improves the glycemic status but also improves sudomotor function, peripheral and autonomic neuropathy, and reduces vascular inflammation in type 2 diabetes.
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study
The results indicate that ranirestat is effective on DPN (Japic CTI-121994) and no clinically significant effects on safety parameters including hepatic and renal functions were observed.
Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis
It is concluded that ARIs could ameliorate cardiac automatic neuropathy especially mild or asymptomatic DCAN but need further investigation.
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
No statistically significant difference was found between aldose reductase inhibitors and placebo in the treatment of diabetic polyneuropathy, and three compounds had dose limiting adverse events that lead to their withdrawal from human use.


Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Twenty milligrams ranirestat per day improves NCV and VPT following 60 weeks of administration and maintains the improved nerve function observed in patients with diabetic sensorimotor polyneuropathy after completing a 12-week nerve biopsy study.
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
The effects of fidarestat-treatment on nerve conduction and the subjective symptoms of diabetic neuropathy provide evidence that this treatment alters the progression of diabetes neuropathy.
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
Even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN, but >80% suppression of nerve sorbitol content is required.
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Whether AS-3201 penetrates the sural nerve and inhibits sorbitol and fructose accumulation in patients with diabetic sensorimotor polyneuropathy (DSP) is investigated to confirm the electrophysiological suggestion that the drug delays progression or leads to regression of DSP.
Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Observations suggest that epalrestat may have therapeutic value at the early stage of diabetic neuropathy and that the pupillary light reflex and minimum latency of the F-wave may be useful indicators of diabetic Neuropathy.
Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy
The C64 quantitative tuning fork analysis is useful in the diagnosis of diabetic polyneuropathy, and as a measure of the severity of the neuropathological symptoms of this condition, as well as its effects on subjective symptoms in patients with diabetic polyNEuropathy.